Aura Biosciences Inc Asset Resilience Ratio
Aura Biosciences Inc asset resilience ratio. Aura Biosciences Inc (AURA) has an Asset Resilience Ratio of 21.75% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Aura Biosciences Inc (AURA) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Aura Biosciences Inc (2021–2025)
Asset resilience ratio of Aura Biosciences Inc from 2021 to 2025. This chart shows how Aura Biosciences Inc's Asset Resilience Ratio has changed over time. Read AURA total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Aura Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see AURA total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $29.94 Million | 21.75% |
| Total Liquid Assets | $29.94 Million | 21.75% |
Asset Resilience Insights
- Good Liquidity Position: Aura Biosciences Inc maintains a healthy 21.75% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Aura Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Aura Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Aura Biosciences Inc Asset Resilience Ratio by Year (2021–2025)
Aura Biosciences Inc asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for Aura Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 50.01% | $84.73 Million | $169.43 Million | -15.42pp |
| 2024-12-31 | 65.42% | $119.40 Million | $182.50 Million | -7.14pp |
| 2023-12-31 | 72.56% | $185.09 Million | $255.07 Million | +42.54pp |
| 2022-12-31 | 30.02% | $67.23 Million | $223.94 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $160.03 Million | -- |
About Aura Biosciences Inc
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the … Read more